Millions of Americans whose livers develop scar tissue due to a common disease now have the first approved drug, Rezdiffra, to treat the condition, the U.S. Food and Drug Administration announced Thursday.
The condition is called non-cirrhotic non-alcoholic steatohepatitis (NASH). NASH with liver scarring is thought to affect up to 8 million Americans. It’s often tied to high blood pressure and type 2 diabetes, the FDA explained in a statement.
“Previously, patients with NASH who also have notable liver scarring did not have a medication that could directly address their liver damage,” said Dr. Nikolay Nikolov, acting director of the Office of Immunology and Inflammation in the FDA’s Center for Drug Evaluation and Research.